• Trial Statistics, Trial Design and AI with Dr. C Michael Gibson
    Feb 29 2024

    Dr Gibson and Dr Nero discuss the oft maligned issue of medical statistics. Their discussion covers the pros and cons of traditional Cox proportional hazards regression models and Kaplan-Meier curves and newer techniques including win ratios. They then dip their toes into AI. A great overview by one of our leading clinical trialists.

    Show more Show less
    34 mins
  • Deep Dive into Lp(a) with Dr Steven Nissen Part 2 of 2
    Feb 19 2024

    This episode is a deep dive into Lipoprotein a with Dr Steven Nissen from the Cleveland Clinic.  He and Dr Nero discuss the genetics of Lp(a), its pathophysiology, current treatment strategies and research into lowering Lp(a) levels.  This is a fascinating conversation that also discusses the role of coronary inflammation in the work of Dr. Paul Ridker as well as the role of CT angiography in future clinical trials.

    Show more Show less
    48 mins
  • Lp(a): a basic clinical approach with Dr. Steven Nissen Part 1 of 2
    Feb 13 2024

    Dr Steven Nissen from the Cleveland Clinic discuses with Dr. Thomas Nero the basic clinical approach to Lp(a) with need for routine testing and a few simple case studies.  In the second (longer podcast) they take a deep deep dive into Lp(a) genetic, pathophysiology and the current research trials.  

    Show more Show less
    11 mins
  • Coronary Artery Disease in the Endurance Athlete with Dr Aaron Baggish
    Feb 1 2024

    Dr Thomas Nero speaks with Dr Aaron Baggish about coronary artery disease in the endurance athlete (and non-athlete as well!)  They discuss cardiovascular testing in Masters athletes including ETT, coronary calcium scoring and CT angiography as well as risk factor identification, inflammation, physical & emotional stress and ongoing research. Dr Baggish is  a Professor of Sports Cardiology at Université de Lausanne and founder of the  Cardiovascular Performance Program, Massachusetts General Hospital, Harvard Medical School.  He has been team cardiologist for USA rowing, US Soccer, and the New England Patriots.  He was the medical director for the Boston Marathon and is a consultant to the IADA, IOC and FIFA.  

    Show more Show less
    42 mins
  • Atrial Fibrillation and Clinical Trials with Dr John Mandrola
    Dec 26 2023

    Dr Mandrola discusses recent trail data with Dr. Thomas Nero including the results from Artesia, NOAH Afnet 6, Frail AF, Azalea and Oceanic-AF.  They also discuss Left Atrial Appendage Occlusion and utility of wearable devices.  Finally, a shout out to Dr. Andre Foy and his work on multi-morbidity and its role in clinical trial interpretation.

    Show more Show less
    49 mins
  • Coronary Calcium Score and CT Coronary Angiography with Dr. Mathew Budoff
    Dec 3 2023

    Dr. Thomas Nero speaks with Dr. Mathew Budoff about Coronary Calcium Scoring, CT Coronary Angiography and cardiovascular outcomes.  The discussion goes beyond basic risk factor enhancement, highlighting its role to help evaluate disease progression, power future clinical trials and determine efficacy of therapy.  Along the way, they discuss coronary inflammation, perivascular adipose tissue imaging and fat attenuation index (FAI) as well as diving into the plaque stabilizing effects of EPA.   

    Show more Show less
    25 mins
  • Dr Elizabeth Ofili and The African American Heart Study
    Nov 26 2023

    Dr. Elizabeth Ofili discusses the African American Heart Study with Dr. Thomas Nero.  They also discuss her work at the NIH and the African American Heart Failure Trial and the role of community based pragmatic clinical trials.

    Show more Show less
    34 mins
  • Anticoagulation, Thombin Generation and Factor XI inhibition in ACS and Atrial Fibrillation with Dr C. Michael Gibson
    Jun 25 2023

    Dr. Thomas Nero discusses current therapy with Factor X inhibitors, the new research with Factor XI inhibition and specifically the enrolling Milvexian clinical trials with Dr. C Micahel Gibson.  In addition they discuss, the addition of these medications along wiht anti-platelet therapy, Lp(a) and other interesting current and future research in cardiovascular disease.

    Show more Show less
    30 mins